Tsukamoto H - Search Results

1

Complement-targeted therapy: development of C5- and C5a-targeted inhibition.

Horiuchi T, Tsukamoto H. Horiuchi T, et al. Among authors: tsukamoto h. Inflamm Regen. 2016 Jun 3;36:11. doi: 10.1186/s41232-016-0013-6. eCollection 2016. Inflamm Regen. 2016. PMID: 29259684 Free PMC article. Review.

2

Molecular bases for human complement C7 polymorphisms, C7*3 and C7*4.

Horiuchi T, Nishimukai H, Okiura T, Nishimura K, Nishizaka H, Kojima T, Tsukamoto H, Hayashi K, Harada M. Horiuchi T, et al. Among authors: tsukamoto h. Biochem Biophys Res Commun. 2002 Nov 1;298(3):450-5. doi: 10.1016/s0006-291x(02)02481-6. Biochem Biophys Res Commun. 2002. PMID: 12413962

3

[Clinical aspects of the complement system].

Tsukamoto H, Horiuchi T. Tsukamoto H, et al. Rinsho Byori. 2006 Jul;54(7):757-62. Rinsho Byori. 2006. PMID: 16913667 Review. Japanese.

4

Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab.

Mitoma H, Horiuchi T, Tsukamoto H, Tamimoto Y, Kimoto Y, Uchino A, To K, Harashima S, Hatta N, Harada M. Mitoma H, et al. Among authors: tsukamoto h. Arthritis Rheum. 2008 May;58(5):1248-57. doi: 10.1002/art.23447. Arthritis Rheum. 2008. PMID: 18438840 Free article.

5

The cytotoxic effects of certolizumab pegol and golimumab mediated by transmembrane tumor necrosis factor α.

Ueda N, Tsukamoto H, Mitoma H, Ayano M, Tanaka A, Ohta S, Inoue Y, Arinobu Y, Niiro H, Akashi K, Horiuchi T. Ueda N, et al. Among authors: tsukamoto h. Inflamm Bowel Dis. 2013 May;19(6):1224-31. doi: 10.1097/MIB.0b013e318280b169. Inflamm Bowel Dis. 2013. PMID: 23619715

6

Molecular mechanisms of action of anti-TNF-α agents - Comparison among therapeutic TNF-α antagonists.

Mitoma H, Horiuchi T, Tsukamoto H, Ueda N. Mitoma H, et al. Among authors: tsukamoto h. Cytokine. 2018 Jan;101:56-63. doi: 10.1016/j.cyto.2016.08.014. Epub 2016 Aug 24. Cytokine. 2018. PMID: 27567553 Review.

7

A novel scoring system based on common laboratory tests predicts the efficacy of TNF-inhibitor and IL-6 targeted therapy in patients with rheumatoid arthritis: a retrospective, multicenter observational study.

Nakagawa J, Koyama Y, Kawakami A, Ueki Y, Tsukamoto H, Horiuchi T, Nagano S, Uchino A, Ota T, Akahoshi M, Akashi K. Nakagawa J, et al. Among authors: tsukamoto h. Arthritis Res Ther. 2017 Aug 11;19(1):185. doi: 10.1186/s13075-017-1387-9. Arthritis Res Ther. 2017. PMID: 28800780 Free PMC article.

8

Characterization of caspase-8L: a novel isoform of caspase-8 that behaves as an inhibitor of the caspase cascade.

Himeji D, Horiuchi T, Tsukamoto H, Hayashi K, Watanabe T, Harada M. Himeji D, et al. Among authors: tsukamoto h. Blood. 2002 Jun 1;99(11):4070-8. doi: 10.1182/blood.v99.11.4070. Blood. 2002. PMID: 12010809 Free article.

9

Association of a four-amino acid residue insertion polymorphism of the HS1 gene with systemic lupus erythematosus: molecular and functional analysis.

Otsuka J, Horiuchi T, Yoshizawa S, Tsukamoto H, Sawabe T, Kikuchi Y, Himeji D, Koyama T, Mitoma H, Watanabe T, Harada M. Otsuka J, et al. Among authors: tsukamoto h. Arthritis Rheum. 2004 Mar;50(3):871-81. doi: 10.1002/art.20192. Arthritis Rheum. 2004. PMID: 15022330 Free article.

10

Novel mutations in TNFRSF1A in patients with typical tumor necrosis factor receptor-associated periodic syndrome and with systemic lupus erythematosus in Japanese.

Horiuchi T, Tsukamoto H, Mitoma H, Miyagawa H, Tamimoto Y, Yoshizawa S, Harada M, Hayashi K, Hashimura C, Oribe M, Okamura S. Horiuchi T, et al. Among authors: tsukamoto h. Int J Mol Med. 2004 Nov;14(5):813-8. Int J Mol Med. 2004. PMID: 15492850

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,065 results

Search Page